Goldman Sachs Group set a GBX 1,900 ($24.83) price objective on GlaxoSmithKline (LON:GSK) in a research note issued to investors on Monday. The brokerage currently has a buy rating on the stock.

Other research analysts also recently issued research reports about the stock. Jefferies Financial Group set a GBX 1,775 ($23.19) target price on shares of GlaxoSmithKline and gave the company a buy rating in a research report on Thursday, August 16th. Liberum Capital reissued a buy rating and issued a GBX 1,630 ($21.30) price objective on shares of GlaxoSmithKline in a research report on Wednesday, August 15th. Shore Capital reissued a buy rating on shares of GlaxoSmithKline in a research report on Wednesday, August 15th. Berenberg Bank reissued a buy rating and issued a GBX 1,790 ($23.39) price objective on shares of GlaxoSmithKline in a research report on Thursday, August 23rd. Finally, BNP Paribas set a GBX 1,750 ($22.87) price objective on shares of GlaxoSmithKline and gave the company a buy rating in a research report on Tuesday, September 11th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and eight have issued a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of GBX 1,512.99 ($19.77).

GlaxoSmithKline stock opened at GBX 1,439.20 ($18.81) on Monday. GlaxoSmithKline has a 1-year low of GBX 1,235.20 ($16.14) and a 1-year high of GBX 1,724.50 ($22.53).

The company also recently disclosed a dividend, which will be paid on Thursday, January 10th. Stockholders of record on Thursday, November 15th will be given a GBX 19 ($0.25) dividend. This represents a dividend yield of 1.26%. The ex-dividend date of this dividend is Thursday, November 15th.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Article: Is it better to buy a fund with a higher or lower NAV?

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.